Evidence map›Paper›PMID 28224416›Full record

SynthesisJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2017

The role of NM23 in patients with colorectal cancer: A systematic review and meta-analysis.

Wei Han, Jun Ma, Fang Cao, Cong Zhang, Rong Zhu, Yong-Wei Hu, Min-Bin Chen, Hou-Zhong Ding

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei HanDepartment of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China.
Jun MaDepartment of Urinary Surgery, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, 215300, China.
Fang CaoDepartment of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China.
Cong ZhangDepartment of Urinary Surgery, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, 215300, China.
Rong ZhuDepartment of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China.
Yong-Wei HuDepartment of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China.
Min-Bin ChenDepartment of Radiotherapy and Oncology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China.
Hou-Zhong DingDepartment of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China. dinghouzhong@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This meta-analysis was carried out to evaluate the relationship between NM23 expression and the prognosis of patients with colorectal cancer. We searched PubMed, EMBASE and Web of Science for relevant articles. The pooled odd ratios (ORs) and corresponding 95%CI were calculated to evaluate the prognostic value of NM23 expression in patients with colorectal cancer, and the association between NM23 expression and clinicopathological factors. In total, 2289 patients were pooled from 24 available studies. The incorporative OR combined by 16 studies with overall survival showed that high NM23 expression was associated with better overall survival (OR=0.67, 95%CI: 0.49-0.93, P=0.02, I

Indexed as

Colorectal NeoplasmsDisease-Free SurvivalGene Expression Regulation, NeoplasticHumansLymphatic MetastasisNeoplasm StagingNM23 Nucleoside Diphosphate KinasesOdds RatioPrognosisSurvival AnalysisNM23 Nucleoside Diphosphate KinasesNME1 protein, humancolorectal cancerNM23prognosissurvival and meta-analysis

Identifiers

PMID28224416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.